Raymond James Financial
BCAX

Raymond James Financial’s Bicara Therapeutics BCAX Stock Holding History

Raymond James Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
+11,956
New +$267K ﹤0.01% 4725
2025
Q4 		– Sell
-67,701
Closed -$1.07M – 5354
2025
Q3 		$1.07M Hold
67,701
– – ﹤0.01% 3632
2025
Q2 		$629K Buy
+67,701
New +$807K ﹤0.01% 3866

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Raymond James Financial's BCAX Position: Q2 2026 in Review

Raymond James Financial opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 11,956 shares worth $355K. The stake represents ﹤0.01% of the portfolio and ranks #4725 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in BCAX as recently as Q3 2025.

Raymond James Financial first reported a position in BCAX in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.07M in Q3 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Raymond James Financial held 11,956 shares of Bicara Therapeutics worth $355K as of Q2 2026.
  • Bicara Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4725 holding.
  • Raymond James Financial first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Bicara Therapeutics position peaked at $1.07M in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.